1. Home
  2. FURY vs BMEA Comparison

FURY vs BMEA Comparison

Compare FURY & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fury Gold Mines Limited

FURY

Fury Gold Mines Limited

HOLD

Current Price

$0.59

Market Cap

97.7M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.85

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FURY
BMEA
Founded
2008
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.7M
107.7M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
FURY
BMEA
Price
$0.59
$1.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$1.70
$9.83
AVG Volume (30 Days)
473.4K
1.9M
Earning Date
05-13-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.87
52 Week High
$1.02
$3.07

Technical Indicators

Market Signals
Indicator
FURY
BMEA
Relative Strength Index (RSI) 43.45 68.59
Support Level $0.49 $1.77
Resistance Level $0.63 $2.06
Average True Range (ATR) 0.04 0.17
MACD 0.01 0.06
Stochastic Oscillator 59.65 85.19

Price Performance

Historical Comparison
FURY
BMEA

About FURY Fury Gold Mines Limited

Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: